论文部分内容阅读
目的:探讨左卡尼汀对病毒性心肌炎(VMC)患儿白介素-18(IL-18)及诱导型一氧化氮合酶(iNOS)的影响。方法:将60例病毒性心肌炎患儿随机分为两组各30例,治疗组给予左卡尼汀100 mg/(kg·d)静脉滴注,对照组给予辅酶A 100 U/d和ATP 40 mg/d静脉滴注,疗程均为14 d。采用酶联免疫吸附法检测患儿治疗前后血清IL-18水平,比色法检测患儿治疗前后血清iNOS水平。结果:对照组治疗前后IL-18、iNOS水平比较差异无统计学意义(P>0.05);治疗组治疗后血清IL-18、iNOS水平显著下降,与治疗前比较差异有统计学意义[(133.66±44.82)vs(271.43±87.50),(8.31±2.19)vs(17.75±4.32),P<0.01],与对照组比较差异亦有统计学意义[(133.66±44.82)vs(243.29±80.93),(8.31±2.19)vs(14.18±3.94),P<0.01]。结论:左卡尼汀可降低VMC患儿血清IL-18及iNOS水平,对VMC有良好的治疗作用。
Objective: To investigate the effects of levocarnitine on interleukin-18 (IL-18) and inducible nitric oxide synthase (iNOS) in children with viral myocarditis (VMC). Methods: Sixty children with viral myocarditis were randomly divided into two groups of 30 patients. The patients in the treatment group were treated with levocarnitine 100 mg / (kg · d) intravenously. The control group was given coenzyme A 100 U / d and ATP 40 mg / d intravenous infusion, treatment were 14 d. Serum levels of IL-18 in children before and after treatment were detected by enzyme-linked immunosorbent assay. Serum iNOS levels in children before and after treatment were detected by colorimetry. Results: The levels of IL-18 and iNOS in the control group had no significant difference before and after treatment (P> 0.05). The levels of IL-18 and iNOS in the treatment group decreased significantly after treatment, with significant difference compared with that before treatment [(133.66 The difference was statistically significant compared with the control group [(133.66 ± 44.82) vs (243.29 ± 80.93) vs (44.82 vs 271.43 ± 87.50 vs 8.31 ± 2.19 vs 17.75 ± 4.32, P <0.01] (8.31 ± 2.19) vs (14.18 ± 3.94), P <0.01]. Conclusion: L-carnitine can reduce the serum levels of IL-18 and iNOS in children with VMC and has a good therapeutic effect on VMC.